

DMB

Display Date	6.7.99
Publication Date	6.8.99
Certifier	Michael W. Bley

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

**Open Meeting for Representatives of Health Professional Organizations; Public Meeting**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of public meeting.

---

**SUMMARY:** The Food and Drug Administration (FDA) is announcing a public meeting with representatives of health professional organizations. The public meeting will be chaired by Sharon Smith Holston, Deputy Commissioner for External Affairs. The two primary topics on the agenda for this meeting will be managing risks from medical product use and pediatric clinical studies.

**DATES:** The public meeting will be held on Tuesday, June 15, 1999, from 1:30 p.m. to 3:30 p.m.

**ADDRESSES:** The public meeting will be held at the Holiday Inn Bethesda, 8210 Wisconsin Ave., Bethesda, MD.


**FOR FURTHER INFORMATION CONTACT:** Peter H. Rheinstein, Office of Health Affairs (HFY-40), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-6630.

Those persons interested in attending this meeting should call Betty Palsgrove at 301-827-6618 to register. Registration may also be transmitted by FAX 1-800-344-3332 or 301-443-2446. Please include the name and title of the person attending, the name of the organization, address, and telephone number. There is no registration fee, however, space is limited. Persons will be registered in the order in which calls are received.

**SUPPLEMENTARY INFORMATION:** The purpose of the public meeting is to provide an opportunity for representatives of health professional organizations and other interested persons to be briefed by senior FDA staff. It will also provide an opportunity for informal discussion on these topics of particular interest to health professional organizations.

The scheduled presenters for this meeting will be Janet Woodcock, Director, Center for Drug Evaluation and Research (CDER) and M. Diane Murphy, Director, Office of Drug Evaluation IV, CDER.

Dated: June 2, 1999



William K. Hubbard  
Associate Commissioner for Policy Coordination

[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

**BILLING CODE 4160-01-F**

**CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL**

